Charles A. Gersbach, Ph.D. - Publications

Biomedical Engineering Duke University, Durham, NC 

107 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Beyersdorf JP, Bawage S, Iglesias N, Peck HE, Hobbs RA, Wroe JA, Zurla C, Gersbach CA, Santangelo PJ. Robust, Durable Gene Activation In Vivo via mRNA-Encoded Activators. Acs Nano. PMID 35357116 DOI: 10.1021/acsnano.1c10631  0.303
2021 Pickar-Oliver A, Gough V, Bohning JD, Liu S, Robinson-Hamm JN, Daniels H, Majoros WH, Devlin G, Asokan A, Gersbach CA. Full-length Dystrophin Restoration via Targeted Genomic Integration by AAV-CRISPR in a Humanized Mouse Model of Duchenne Muscular Dystrophy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 34509668 DOI: 10.1016/j.ymthe.2021.09.003  0.336
2021 Gemberling MP, Siklenka K, Rodriguez E, Tonn-Eisinger KR, Barrera A, Liu F, Kantor A, Li L, Cigliola V, Hazlett MF, Williams CA, Bartelt LC, Madigan VJ, Bodle JC, Daniels H, ... ... Gersbach CA, et al. Transgenic mice for in vivo epigenome editing with CRISPR-based systems. Nature Methods. PMID 34341582 DOI: 10.1038/s41592-021-01207-2  0.366
2021 Abdeen AA, Cosgrove BD, Gersbach CA, Saha K. Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science. Annual Review of Biomedical Engineering. PMID 33909475 DOI: 10.1146/annurev-bioeng-122019-121602  0.319
2021 Saha K, Sontheimer EJ, Brooks PJ, Dwinell MR, Gersbach CA, Liu DR, Murray SA, Tsai SQ, Wilson RC, Anderson DG, Asokan A, Banfield JF, Bankiewicz KS, Bao G, Bulte JWM, et al. The NIH Somatic Cell Genome Editing program. Nature. 592: 195-204. PMID 33828315 DOI: 10.1038/s41586-021-03191-1  0.478
2020 Carullo NVN, Phillips Iii RA, Simon RC, Soto SAR, Hinds JE, Salisbury AJ, Revanna JS, Bunner KD, Ianov L, Sultan FA, Savell KE, Gersbach CA, Day JJ. Enhancer RNAs predict enhancer-gene regulatory links and are critical for enhancer function in neuronal systems. Nucleic Acids Research. PMID 32810208 DOI: 10.1093/Nar/Gkaa671  0.418
2020 Cosgrove BD, Gersbach CA. Unwinding the Role of FACT in Cas9-based Genome Editing. Molecular Cell. 79: 365-367. PMID 32763224 DOI: 10.1016/J.Molcel.2020.07.016  0.357
2020 Kwon JB, Vankara A, Ettyreddy AR, Bohning JD, Gersbach CA. Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators. Stem Cell Reports. PMID 32330446 DOI: 10.1016/J.Stemcr.2020.03.026  0.406
2020 Dicks A, Wu CL, Steward N, Adkar SS, Gersbach CA, Guilak F. Prospective isolation of chondroprogenitors from human iPSCs based on cell surface markers identified using a CRISPR-Cas9-generated reporter. Stem Cell Research & Therapy. 11: 66. PMID 32070421 DOI: 10.1186/S13287-020-01597-8  0.359
2019 Huang J, Chen M, Xu ES, Luo L, Ma Y, Huang W, Floyd W, Klann TS, Kim SY, Gersbach CA, Cardona DM, Kirsch DG. Genome-wide CRISPR Screen to Identify Genes that Suppress Transformation in the Presence of Endogenous Kras. Scientific Reports. 9: 17220. PMID 31748650 DOI: 10.1038/S41598-019-53572-W  0.34
2019 Pickar-Oliver A, Black JB, Lewis MM, Mutchnick KJ, Klann TS, Gilcrest KA, Sitton MJ, Nelson CE, Barrera A, Bartelt LC, Reddy TE, Beisel CL, Barrangou R, Gersbach CA. Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells. Nature Biotechnology. PMID 31548729 DOI: 10.1038/S41587-019-0235-7  0.389
2019 Kwon JB, Gersbach CA. Jumping at the chance for precise DNA integration. Nature Biotechnology. PMID 31371821 DOI: 10.1038/S41587-019-0210-3  0.337
2019 Nance ME, Shi R, Hakim CH, Wasala NB, Yue Y, Pan X, Zhang T, Robinson CA, Duan SX, Yao G, Yang NN, Chen SJ, Wagner KR, Gersbach CA, Duan D. AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31327755 DOI: 10.1016/J.Ymthe.2019.06.012  0.342
2019 Kocak DD, Josephs EA, Bhandarkar V, Adkar SS, Kwon JB, Gersbach CA. Increasing the specificity of CRISPR systems with engineered RNA secondary structures. Nature Biotechnology. PMID 30988504 DOI: 10.1038/S41587-019-0095-1  0.379
2019 Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, Robinson-Hamm JN, Bulaklak K, Castellanos Rivera RM, Collier JH, Asokan A, Gersbach CA. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nature Medicine. PMID 30778238 DOI: 10.1038/S41591-019-0344-3  0.355
2019 Chen LF, Lin YT, Gallegos DA, Hazlett MF, Gómez-Schiavon M, Yang MG, Kalmeta B, Zhou AS, Holtzman L, Gersbach CA, Grandl J, Buchler NE, West AE. Enhancer Histone Acetylation Modulates Transcriptional Bursting Dynamics of Neuronal Activity-Inducible Genes. Cell Reports. 26: 1174-1188.e5. PMID 30699347 DOI: 10.1016/J.Celrep.2019.01.032  0.36
2018 Hakim CH, Wasala NB, Nelson CE, Wasala LP, Yue Y, Louderman JA, Lessa TB, Dai A, Zhang K, Jenkins GJ, Nance ME, Pan X, Kodippili K, Yang NN, Chen SJ, ... Gersbach CA, et al. AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice. Jci Insight. 3. PMID 30518686 DOI: 10.1172/Jci.Insight.124297  0.319
2018 Adkar SS, Wu CL, Willard VP, Dicks A, Ettyreddy A, Steward N, Bhutani N, Gersbach CA, Guilak F. Step-Wise Chondrogenesis of Human Induced Pluripotent Stem Cells and Purification Via a Reporter Allele Generated by CRISPR-Cas9 Genome Editing. Stem Cells (Dayton, Ohio). PMID 30378731 DOI: 10.1002/Stem.2931  0.382
2018 McDowell IC, Barrera A, D'Ippolito AM, Vockley CM, Hong LK, Leichter SM, Bartelt LC, Majoros WH, Song L, Safi A, Koçak DD, Gersbach CA, Hartemink AJ, Crawford GE, Engelhardt BE, et al. Glucocorticoid receptor recruits to enhancers and drives activation by motif-directed binding. Genome Research. PMID 30097539 DOI: 10.1101/Gr.233346.117  0.32
2018 D'Ippolito AM, McDowell IC, Barrera A, Hong LK, Leichter SM, Bartelt LC, Vockley CM, Majoros WH, Safi A, Song L, Gersbach CA, Crawford GE, Reddy TE. Pre-established Chromatin Interactions Mediate the Genomic Response to Glucocorticoids. Cell Systems. PMID 30031775 DOI: 10.1016/J.Cels.2018.06.007  0.379
2018 Holtzman L, Gersbach CA. Editing the Epigenome: Reshaping the Genomic Landscape. Annual Review of Genomics and Human Genetics. PMID 29852072 DOI: 10.1146/Annurev-Genom-083117-021632  0.422
2018 Black JB, Gersbach CA. Synthetic transcription factors for cell fate reprogramming. Current Opinion in Genetics & Development. 52: 13-21. PMID 29803990 DOI: 10.1016/J.Gde.2018.05.001  0.417
2018 Huynh NPT, Brunger JM, Gloss CC, Moutos FT, Gersbach CA, Guilak F. Genetic Engineering of Mesenchymal Stem Cells for Differential Matrix Deposition on 3DWoven Scaffold. Tissue Engineering. Part A. PMID 29756533 DOI: 10.1089/Ten.Tea.2017.0510  0.343
2018 Thakore PI, Kwon JB, Nelson CE, Rouse DC, Gemberling MP, Oliver ML, Gersbach CA. RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. Nature Communications. 9: 1674. PMID 29700298 DOI: 10.1038/S41467-018-04048-4  0.417
2018 Klann TS, Crawford GE, Reddy TE, Gersbach CA. Screening Regulatory Element Function with CRISPR/Cas9-based Epigenome Editing. Methods in Molecular Biology (Clifton, N.J.). 1767: 447-480. PMID 29524151 DOI: 10.1007/978-1-4939-7774-1_25  0.37
2018 Huang J, Chen M, Whitley MJ, Kuo H, Xu ES, Walens A, Mowery YM, Mater DV, Eward WC, Cardona DM, Luo L, Ma Y, Lopez OM, Nelson CE, Robinson-Hamm JN, ... ... Gersbach CA, et al. Abstract A17: Generation and comparison of CRISPR/Cas9 and Cre-mediated genetically engineered mouse models of sarcoma Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Sarcomas17-A17  0.338
2017 Manandhar D, Song L, Kabadi A, Kwon JB, Edsall LE, Ehrlich M, Tsumagari K, Gersbach CA, Crawford GE, Gordân R. Incomplete MyoD-induced transdifferentiation is associated with chromatin remodeling deficiencies. Nucleic Acids Research. PMID 28977539 DOI: 10.1093/Nar/Gkx773  0.46
2017 Nelson CE, Robinson-Hamm JN, Gersbach CA. Genome engineering: a new approach to gene therapy for neuromuscular disorders. Nature Reviews. Neurology. PMID 28960187 DOI: 10.1038/Nrneurol.2017.126  0.435
2017 Adkar SS, Brunger JM, Willard VP, Wu CL, Gersbach CA, Guilak F. Genome Engineering for Personalized Arthritis Therapeutics. Trends in Molecular Medicine. PMID 28887050 DOI: 10.1016/J.Molmed.2017.08.002  0.373
2017 Polstein L, Juhas M, Hanna G, Bursac N, Gersbach CA. An Engineered Optogenetic Switch for Spatiotemporal Control of Gene Expression, Cell Differentiation, and Tissue Morphogenesis. Acs Synthetic Biology. PMID 28793186 DOI: 10.1021/Acssynbio.7B00147  0.398
2017 Huang J, Chen M, Whitley MJ, Kuo HC, Xu ES, Walens A, Mowery YM, Van Mater D, Eward WC, Cardona DM, Luo L, Ma Y, Lopez OM, Nelson CE, Robinson-Hamm JN, ... ... Gersbach CA, et al. Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma. Nature Communications. 8: 15999. PMID 28691711 DOI: 10.1038/Ncomms15999  0.333
2017 Black JB, Perez-Pinera P, Gersbach CA. Mammalian Synthetic Biology: Engineering Biological Systems. Annual Review of Biomedical Engineering. 19: 249-277. PMID 28633563 DOI: 10.1146/Annurev-Bioeng-071516-044649  0.403
2017 Brunger JM, Zutshi A, Willard VP, Gersbach CA, Guilak F. Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs. Stem Cell Reports. PMID 28457885 DOI: 10.1016/J.Stemcr.2017.03.022  0.353
2017 Klann TS, Black JB, Chellappan M, Safi A, Song L, Hilton IB, Crawford GE, Reddy TE, Gersbach CA. CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nature Biotechnology. PMID 28369033 DOI: 10.1038/Nbt.3853  0.37
2017 Farhang N, Brunger JM, Stover JD, Thakore PI, Lawrence B, Guilak F, Gersbach CA, Setton LA, Bowles RD. CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments. Tissue Engineering. Part A. PMID 28095751 DOI: 10.1089/Ten.Tea.2016.0441  0.348
2016 Brunger JM, Zutshi A, Willard VP, Gersbach CA, Guilak F. CRISPR/Cas9 editing of induced pluripotent stem cells for engineering inflammation-resistant tissues. Arthritis & Rheumatology (Hoboken, N.J.). PMID 27813286 DOI: 10.1002/Art.39982  0.328
2016 Housden BE, Muhar M, Gemberling M, Gersbach CA, Stainier DY, Seydoux G, Mohr SE, Zuber J, Perrimon N. Loss-of-function genetic tools for animal models: cross-species and cross-platform differences. Nature Reviews. Genetics. PMID 27795562 DOI: 10.1038/Nrg.2016.118  0.381
2016 Robinson-Hamm JN, Gersbach CA. Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy. Human Genetics. PMID 27542949 DOI: 10.1007/S00439-016-1725-Z  0.45
2016 Black JB, Adler AF, Wang HG, D'Ippolito AM, Hutchinson HA, Reddy TE, Pitt GS, Leong KW, Gersbach CA. Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells. Cell Stem Cell. PMID 27524438 DOI: 10.1016/J.Stem.2016.07.001  0.465
2016 Moutos FT, Glass KA, Compton SA, Ross AK, Gersbach CA, Guilak F, Estes BT. Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing. Proceedings of the National Academy of Sciences of the United States of America. PMID 27432980 DOI: 10.1073/Pnas.1601639113  0.332
2016 Nelson CE, Gersbach CA. Engineering Delivery Vehicles for Genome Editing. Annual Review of Chemical and Biomolecular Engineering. PMID 27146557 DOI: 10.1146/Annurev-Chembioeng-080615-034711  0.413
2016 Thakore PI, Black JB, Hilton IB, Gersbach CA. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nature Methods. 13: 127-37. PMID 26820547 DOI: 10.1038/Nmeth.3733  0.451
2016 Maeder ML, Gersbach CA. Genome Editing Technologies for Gene and Cell Therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26755333 DOI: 10.1038/Mt.2016.10  0.443
2016 Thakore PI, Gersbach CA. Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors. Methods in Molecular Biology (Clifton, N.J.). 1338: 71-88. PMID 26443215 DOI: 10.1007/978-1-4939-2932-0_7  0.433
2016 Ousterout DG, Gersbach CA. The Development of TALE Nucleases for Biotechnology. Methods in Molecular Biology (Clifton, N.J.). 1338: 27-42. PMID 26443211 DOI: 10.1007/978-1-4939-2932-0_3  0.413
2016 Kwon JB, Gersbach CA. 626. Directing Skeletal Myogenic Progenitor Cell Lineage Specification with CRISPR/Cas9 Transcriptional Activators Molecular Therapy. 24: S248. DOI: 10.1016/S1525-0016(16)33434-7  0.439
2016 Kabadi AM, Klann TS, Chellappan M, Kwon J, Reddy TE, Gersbach CA. 525. Directed Molecular Evolution of Transcription Factors in Mammalian Cells for Enhanced Directed Cell Differentiation Molecular Therapy. 24: S210. DOI: 10.1016/S1525-0016(16)33334-2  0.449
2016 Robinson-Hamm JN, Nelson CE, Rivera RMC, Aartsma-Rus A, Asokan A, Gersbach CA. 504. Restoration of Dystrophin Expression by Gene Editing with S. aureus Cas9 in Models of Duchenne Muscular Dystrophy Molecular Therapy. 24: S201. DOI: 10.1016/S1525-0016(16)33313-5  0.459
2016 Nelson C, Gemberling M, Hakim CH, Ousterout DG, Thakore PI, Castellanos RM, Madhavan S, Pan X, Ran FA, Yan W, Asokan A, Zhang F, Duan D, Gersbach CA. 482. Local and Systemic Gene Editing in a Mouse Model of Duchenne Muscular Dystrophy Molecular Therapy. 24: S191. DOI: 10.1016/S1525-0016(16)33291-9  0.38
2016 Thakore PI, Shivakumar NK, Gersbach CA. 385. Inhibiting the Myostatin Signaling Pathway using CRISPR/Cas9-Based Repressors Molecular Therapy. 24: S153. DOI: 10.1016/S1525-0016(16)33194-X  0.419
2016 Adkar SS, Willard VP, Brunger JM, Shiao KT, Gersbach CA, Guilak F. 318. Targeted Genome Editing of Human Induced Pluripotent Stem Cells Using CRISPR/CAS9 to Generate a Knock-in Type II Collagen Reporter for the Purification of Chondrogenic Cells Molecular Therapy. 24: S128. DOI: 10.1016/S1525-0016(16)33127-6  0.405
2016 Tycko J, Huston N, Robinson-Hamm JN, Wilson C, Gersbach CA, Hsu PD, Bumcrot D. 317. Screening S. Aureus CRISPR-Cas9 Paired-Guide RNAs for Efficient Targeted Deletion in Duchenne Muscular Dystrophy Molecular Therapy. 24: S127-S128. DOI: 10.1016/S1525-0016(16)33126-4  0.415
2016 Josephs EA, Kocak DD, Fitzgibbon CJ, McMenemy J, Gersbach CA, Marszalek PE. A Molecule-Scale View of the Structure and Specificity of the RNA-Guided Endonuclease Cas9 Biophysical Journal. 110: 238a. DOI: 10.1016/J.Bpj.2015.11.1311  0.377
2015 Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX, Asokan A, Zhang F, Duan D, Gersbach CA. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science (New York, N.Y.). PMID 26721684 DOI: 10.1126/Science.Aad5143  0.393
2015 Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Reddy TE, Crawford GE, Gersbach CA. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nature Methods. PMID 26501517 DOI: 10.1038/Nmeth.3630  0.452
2015 Josephs EA, Kocak DD, Fitzgibbon CJ, McMenemy J, Gersbach CA, Marszalek PE. Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage. Nucleic Acids Research. 43: 8924-41. PMID 26384421 DOI: 10.1093/Nar/Gkv892  0.346
2015 Polstein LR, Perez-Pinera P, Kocak DD, Vockley CM, Bledsoe P, Song L, Safi A, Crawford GE, Reddy TE, Gersbach CA. Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators. Genome Research. PMID 26025803 DOI: 10.1101/Gr.179044.114  0.468
2015 Gibson TM, Gersbach CA. Single-molecule analysis of myocyte differentiation reveals bimodal lineage commitment. Integrative Biology : Quantitative Biosciences From Nano to Macro. 7: 663-71. PMID 25953198 DOI: 10.1039/C5Ib00057B  0.359
2015 Frank CL, Liu F, Wijayatunge R, Song L, Biegler MT, Yang MG, Vockley CM, Safi A, Gersbach CA, Crawford GE, West AE. Regulation of chromatin accessibility and Zic binding at enhancers in the developing cerebellum. Nature Neuroscience. 18: 647-56. PMID 25849986 DOI: 10.1038/Nn.3995  0.362
2015 Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nature Biotechnology. 33: 510-7. PMID 25849900 DOI: 10.1038/Nbt.3199  0.449
2015 Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nature Communications. 6: 6244. PMID 25692716 DOI: 10.1038/Ncomms7244  0.415
2015 Diekman BO, Thakore PI, O'Connor SK, Willard VP, Brunger JM, Christoforou N, Leong KW, Gersbach CA, Guilak F. Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells. Tissue Engineering. Part A. 21: 1261-74. PMID 25517798 DOI: 10.1089/Ten.Tea.2014.0240  0.362
2015 Kabadi AM, Thakore PI, Vockley CM, Ousterout DG, Gibson TM, Guilak F, Reddy TE, Gersbach CA. Enhanced MyoD-Induced Transdifferentiation to a Myogenic Lineage by Fusion to a Potent Transactivation Domain. Acs Synthetic Biology. 4: 689-99. PMID 25494287 DOI: 10.1021/Sb500322U  0.449
2015 Ousterout DG, Kabadi AM, Thakore PI, Perez-Pinera P, Brown MT, Majoros WH, Reddy TE, Gersbach CA. Correction of dystrophin expression in cells from duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 523-32. PMID 25492562 DOI: 10.1038/Mt.2014.234  0.417
2015 Toth LP, Gersbach CA. 691. A Light-Inducible CRISPR/Cas9 System for Control of Endogenous Gene Activation Molecular Therapy. 23: S275. DOI: 10.1016/S1525-0016(16)34300-3  0.433
2015 Brunger JM, Zutshi A, Willard VP, Gersbach CA, Guilak F. 504. Targeted Genome Engineering of Induced Pluripotent Stem Cells To Produce Auto-Regulated Inflammation Resistance for Musculoskeletal Regenerative Medicine Molecular Therapy. 23: S201-S202. DOI: 10.1016/S1525-0016(16)34113-2  0.409
2015 Thakore PI, D'Ippolito A, Song L, Safi A, Shivakumar NK, Kabadi AM, Bledsoe P, Reddy TE, Crawford GE, Gersbach CA. 485. Targeted Epigenome Editing by CRISPR/Cas9-Based Repressors for Silencing of Distal Regulatory Elements Molecular Therapy. 23: S192-S193. DOI: 10.1016/S1525-0016(16)34094-1  0.48
2015 Nelson CE, Moreb DGOJNREA, Castellanos RM, Ran FA, Yan W, Zhang F, Asokan A, Gersbach CA. 397. Correction of the Dystrophin Gene By the CRISPR/Cas9 System in a Mouse Model of Muscular Dystrophy Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34006-0  0.465
2015 Kabadi AM, Liu F, Gersbach CA. 396. Multiplex CRISPR/Cas9 Genome Engineering for Directing Myogenic Cellular Differentiation Molecular Therapy. 23: S157. DOI: 10.1016/S1525-0016(16)34005-9  0.469
2015 Black J, Adler A, Hutchinson H, Wang H, Pitt G, Leong K, Gersbach C. 59. Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype Molecular Therapy. 23: S26. DOI: 10.1016/S1525-0016(16)33664-4  0.457
2014 Chakraborty S, Ji H, Chen J, Gersbach CA, Leong KW. Vector modifications to eliminate transposase expression following piggyBac-mediated transgenesis. Scientific Reports. 4: 7403. PMID 25492703 DOI: 10.1038/Srep07403  0.393
2014 Chakraborty S, Ji H, Kabadi AM, Gersbach CA, Christoforou N, Leong KW. A CRISPR/Cas9-based system for reprogramming cell lineage specification. Stem Cell Reports. 3: 940-7. PMID 25448066 DOI: 10.1016/J.Stemcr.2014.09.013  0.456
2014 Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA. Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Research. 42: e147. PMID 25122746 DOI: 10.1093/Nar/Gku749  0.472
2014 Kabadi AM, Gersbach CA. Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression. Methods (San Diego, Calif.). 69: 188-97. PMID 25010559 DOI: 10.1016/J.Ymeth.2014.06.014  0.46
2014 Gersbach CA, Perez-Pinera P. Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine. Expert Opinion On Therapeutic Targets. 18: 835-9. PMID 24917359 DOI: 10.1517/14728222.2014.913572  0.487
2014 Gersbach CA, Gaj T, Barbas CF. Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies. Accounts of Chemical Research. 47: 2309-18. PMID 24877793 DOI: 10.1021/Ar500039W  0.464
2014 High K, Gregory PD, Gersbach C. CRISPR technology for gene therapy Nature Medicine. 20: 476-477. PMID 24804755 DOI: 10.1038/Nm.3566  0.338
2014 Glass KA, Link JM, Brunger JM, Moutos FT, Gersbach CA, Guilak F. Tissue-engineered cartilage with inducible and tunable immunomodulatory properties. Biomaterials. 35: 5921-31. PMID 24767790 DOI: 10.1016/J.Biomaterials.2014.03.073  0.311
2014 Polstein LR, Gersbach CA. Light-inducible gene regulation with engineered zinc finger proteins. Methods in Molecular Biology (Clifton, N.J.). 1148: 89-107. PMID 24718797 DOI: 10.1007/978-1-4939-0470-9_7  0.417
2014 Brunger JM, Huynh NP, Guenther CM, Perez-Pinera P, Moutos FT, Sanchez-Adams J, Gersbach CA, Guilak F. Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage. Proceedings of the National Academy of Sciences of the United States of America. 111: E798-806. PMID 24550481 DOI: 10.1073/Pnas.1321744111  0.387
2014 Gersbach CA. Targeted genome and epigenome editing using engineered TALE and CRISPR/Cas9 technologies Molecular Pain. 10: O4. DOI: 10.1186/1744-8069-10-S1-O4  0.509
2013 Ousterout DG, Perez-Pinera P, Thakore PI, Kabadi AM, Brown MT, Qin X, Fedrigo O, Mouly V, Tremblay JP, Gersbach CA. Erratum: Reading Frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients (Molecular Therapy (2013) 21 (1718-1726) DOI: 10.1038/mt.2013.111) Molecular Therapy. 21. PMID 28147288 DOI: 10.1038/Mt.2013.229  0.377
2013 Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nature Methods. 10: 973-6. PMID 23892895 DOI: 10.1038/Nmeth.2600  0.422
2013 Ousterout DG, Perez-Pinera P, Thakore PI, Kabadi AM, Brown MT, Qin X, Fedrigo O, Mouly V, Tremblay JP, Gersbach CA. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1718-26. PMID 23732986 DOI: 10.1038/Mt.2013.111  0.464
2013 Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in Biotechnology. 31: 397-405. PMID 23664777 DOI: 10.1016/J.Tibtech.2013.04.004  0.374
2013 Gibson TM, Gersbach CA. The role of single-cell analyses in understanding cell lineage commitment. Biotechnology Journal. 8: 397-407. PMID 23520130 DOI: 10.1002/Biot.201200201  0.344
2013 Perez-Pinera P, Ousterout DG, Brunger JM, Farin AM, Glass KA, Guilak F, Crawford GE, Hartemink AJ, Gersbach CA. Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nature Methods. 10: 239-42. PMID 23377379 DOI: 10.1038/Nmeth.2361  0.438
2013 Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, ... ... Gersbach CA, et al. Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 266-8. PMID 23369965 DOI: 10.1038/Mt.2013.4  0.376
2013 Bhakta MS, Henry IM, Ousterout DG, Das KT, Lockwood SH, Meckler JF, Wallen MC, Zykovich A, Yu Y, Leo H, Xu L, Gersbach CA, Segal DJ. Highly active zinc-finger nucleases by extended modular assembly. Genome Research. 23: 530-8. PMID 23222846 DOI: 10.1101/Gr.143693.112  0.523
2013 Glass K, Brunger J, Gersbach C, Guilak F. Tunable expression of IL-1Ra in genetically modified mesenchymal stem cells for cartilage tissue engineering Osteoarthritis and Cartilage. 21: S282-S283. DOI: 10.1016/J.Joca.2013.02.591  0.324
2012 Polstein LR, Gersbach CA. Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors. Journal of the American Chemical Society. 134: 16480-3. PMID 22963237 DOI: 10.1021/Ja3065667  0.458
2012 Perez-Pinera P, Ousterout DG, Gersbach CA. Advances in targeted genome editing. Current Opinion in Chemical Biology. 16: 268-77. PMID 22819644 DOI: 10.1016/J.Cbpa.2012.06.007  0.443
2012 Perez-Pinera P, Ousterout DG, Brown MT, Gersbach CA. Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases. Nucleic Acids Research. 40: 3741-52. PMID 22169954 DOI: 10.1093/Nar/Gkr1214  0.479
2011 Gersbach CA, Gaj T, Gordley RM, Mercer AC, Barbas CF. Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase. Nucleic Acids Research. 39: 7868-78. PMID 21653554 DOI: 10.1093/Nar/Gkr421  0.43
2011 Gaj T, Mercer AC, Gersbach CA, Gordley RM, Barbas CF. Structure-guided reprogramming of serine recombinase DNA sequence specificity. Proceedings of the National Academy of Sciences of the United States of America. 108: 498-503. PMID 21187418 DOI: 10.1073/Pnas.1014214108  0.332
2010 Gersbach CA, Gaj T, Gordley RM, Barbas CF. Directed evolution of recombinase specificity by split gene reassembly. Nucleic Acids Research. 38: 4198-206. PMID 20194120 DOI: 10.1093/Nar/Gkq125  0.417
2007 Gersbach CA, Coyer SR, Le Doux JM, García AJ. Biomaterial-mediated retroviral gene transfer using self-assembled monolayers. Biomaterials. 28: 5121-7. PMID 17698189 DOI: 10.1016/J.Biomaterials.2007.07.047  0.399
2007 Pregizer S, Barski A, Gersbach CA, García AJ, Frenkel B. Identification of novel Runx2 targets in osteoblasts: cell type-specific BMP-dependent regulation of Tram2. Journal of Cellular Biochemistry. 102: 1458-71. PMID 17486635 DOI: 10.1002/Jcb.21366  0.433
2007 Gersbach CA, Phillips JE, García AJ. Genetic engineering for skeletal regenerative medicine. Annual Review of Biomedical Engineering. 9: 87-119. PMID 17425467 DOI: 10.1146/Annurev.Bioeng.9.060906.151949  0.411
2007 Gersbach CA, Guldberg RE, García AJ. In vitro and in vivo osteoblastic differentiation of BMP-2- and Runx2-engineered skeletal myoblasts. Journal of Cellular Biochemistry. 100: 1324-36. PMID 17131362 DOI: 10.1002/Jcb.21118  0.432
2007 Phillips JE, Gersbach CA, García AJ. Virus-based gene therapy strategies for bone regeneration. Biomaterials. 28: 211-29. PMID 16928397 DOI: 10.1016/J.Biomaterials.2006.07.032  0.363
2006 Gersbach CA, Le Doux JM, Guldberg RE, García AJ. Inducible regulation of Runx2-stimulated osteogenesis. Gene Therapy. 13: 873-82. PMID 16496016 DOI: 10.1038/Sj.Gt.3302725  0.408
2006 Phillips JE, Gersbach CA, Wojtowicz AM, García AJ. Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation. Journal of Cell Science. 119: 581-91. PMID 16443755 DOI: 10.1242/Jcs.02758  0.315
2006 Gersbach CA, Coyer SR, Le Doux JM, Garcia AJ. 814. Biomaterial-Mediated Retroviral Gene Delivery Molecular Therapy. 13: S315-S316. DOI: 10.1016/J.Ymthe.2006.08.899  0.367
2004 Gersbach CA, Byers BA, Pavlath GK, Guldberg RE, García AJ. Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro. Biotechnology and Bioengineering. 88: 369-78. PMID 15486943 DOI: 10.1002/Bit.20251  0.38
2004 Gersbach CA, Byers BA, Pavlath GK, García AJ. Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype. Experimental Cell Research. 300: 406-17. PMID 15475005 DOI: 10.1016/J.Yexcr.2004.07.031  0.39
2003 García AJ, Guldberg RE, Byers BA, Gersbach CA, Phillips JE. Addressing cell-sourcing limitations with gene therapy. Ieee Engineering in Medicine and Biology Magazine : the Quarterly Magazine of the Engineering in Medicine & Biology Society. 22: 65-70. PMID 14699938 DOI: 10.1109/Memb.2003.1256274  0.395
Show low-probability matches.